Clinical investigation of the impact of low-dose atropine drops on children's myopia progression

Abstract

Background: Myopia is a common and frequently perplexing eye condition. Even at low levels, myopia is now
associated with an increased risk of numerous eye diseases. By preventing the development of myopia, eye health
and quality of life may be improved.
Methods: A total of 66 patients were enrolled in this prospective, experimental study that examined the impact of a
0.01% atropine eye drop on the progression of myopia. It was carried out in an outpatient tertiary medical facility.
Participants must be at least 6 years old and under 15 years old, have myopia or myopic astigmatism, and have their
parents' permission to take part in the study. Children with congenital or developmental delays, systemic illnesses,
ocular pathologies such as amblyopia, strabismus, cataracts, or atropine allergies were excluded.
Results: The spherical equivalent comparison between the baseline and follow-up measurements following the
administration of low-dose atropine drops revealed a significant correlation between the baseline and follow-up
measurements at 12 months (p=0.043) and 18 months (p=0.038). There is no statistically significant correlation
found in the 6-month follow-up comparison.
Conclusions: We came to the conclusion that atropine at low doses should be taken into consideration as a
treatment to control the progression of myopia. To better understand the impact of low-dose atropine on the
progression of myopia, it is advised to conduct additional research in a comparable population over a longer period
of time—three years or more.